Clinical Trial Update: Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating an imaging radiotracer, [18F]-FARAG, in patients with advanced non-small cell lung cancer undergoing PD-1/PD-L1-directed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• [18F]-FARAG

Snippet

Sponsor: CellSight Technologies, Inc. | Conditions: Advanced Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING